Pradyot Dash
Associate Vice President & Head of Research & Development Lentigen Technology, a subsidiary of Miltenyi Biotec
Seminars
Wednesday 20th May 2026
Selective T‑Cell Programming for Combinatorial CAR‑T/TCR‑T Solid Tumor Therapy
12:00 pm
- Describing a combinatorial CAR‑T and TCR‑T strategy for solid tumors enabled by targeted viral engineering
- Paramyxovirus‑based pseudotyping will allow selective programming of distinct T‑cell subsets to generate complementary CAR‑T and TCR‑T products
- Improving tumor recognition and address antigen heterogeneity
